Director, Health Economic Outcomes Research (Remote)

📋 Description

• • Own the end-to-end global evidence strategy for Illumina’s entire molecular-diagnostics portfolio—spanning oncology, reproductive health, rare disease, and emerging applications—ensuring every assay we launch is paired with bullet-proof health-economic justification that payers, regulators, and clinicians trust.
• • Translate complex genomic data into clear, compelling value stories that resonate with HTA bodies, ministries of health, and private insurers across six continents, directly influencing whether a child with a rare disease gains access to life-saving testing or an oncology assay becomes the new standard of care.
• • Architect and execute prospective and real-world evidence studies, micro-costing models, budget-impact analyses, and systematic literature reviews that shape global reimbursement policy and accelerate patient access.
• • Lead a high-caliber, multidisciplinary HEOR team—spanning health economists, epidemiologists, data scientists, and publication managers—while serving as the strategic bridge between Commercial, Medical Affairs, Regulatory, and R&D to ensure every clinical trial design and product launch is grounded in robust value evidence.
• • Establish and maintain relationships with key external stakeholders—KOLs, academic centers, patient-advocacy groups, and payer advisory boards—to co-create evidence priorities and disseminate findings through peer-reviewed journals, congress presentations, and policy white papers.
• • Drive the annual evidence-generation roadmap, aligning it with corporate revenue targets and therapeutic-area strategies; secure and manage multi-million-dollar budgets and timelines, ensuring deliverables meet or exceed quality, compliance, and publication standards.
• • Serve as the primary HEOR spokesperson for Illumina at global forums such as ISPOR, ICER, ESMO, ACMG, and national HTA meetings, translating technical data into persuasive narratives that influence coverage decisions and clinical guidelines.
• • Champion diversity, equity, and inclusion in genomic medicine by embedding health-disparities analyses into study designs and ensuring under-represented populations benefit equally from precision-health advances.
• • Report directly to senior leadership, presenting quarterly evidence-impact dashboards that link study outcomes to revenue, market access, and patient-outcome metrics, while continuously scanning the competitive and regulatory landscape to anticipate future evidence needs.
• • Foster a culture of scientific curiosity and operational excellence within the HEOR function, implementing best-practice SOPs, digital-analytics platforms, and agile project-management methodologies that cut study cycle times and maximize real-world data utility.